N4 Pharma PLC (AIM: N4P) has officially changed its name to Thalia Therapeutics plc, effective March 18, 2026.
N4 Pharma plc (AIM: N4P) CEO Appointment & Name Change Thalia Therapeutics
CEO Appointment, Strategic Update and Name Change to Thalia Therapeutics
N4 Pharma plc (AIM: N4P) Partnership with University of Strathclyde’s CMAC National Facility
Collaboration combines N4 Pharma’s innovative Nuvec® delivery platform with CMAC’s world-class expertise to accelerate development and broaden therapeutic applications
Breakthrough in Targeted Cancer Treatment Sends N4 Pharma Stock Soaring
N4 Pharma PLC (AIM: N4P) shares surged after the company announced that its Nuvec® delivery system had successfully targeted non-small cell lung cancer cells in collaboration with leading US research
Angle PLC (AIM:AGL) Analysis of CTC-DNA and ctDNA using Illumina assay
ANGLE PLC (AIM: AGL, OTCQX: ANPCY) has revealed new research indicating that analysing entire tumour cells in the bloodstream, rather than solely DNA fragments, may offer a more comprehensive understanding
N4 Pharma PLC (AIM:NP4) Directorate Changes
N4 Pharma plc (AIM: N4P), the biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, is pleased to announce the appointment of Dr
N4 Pharma PLC (AIM:N4P) N4 Pharma CEO Q&A Now LIVE
N4 Pharma CEO Q&A Now LIVE
Angle PLC (AIM:AGL OTCQX:ANPCY) Study of ovarian cancer CTCs using Parsortix
ANGLE PLC (AIM: AGL, OTCQX: ANPCY), a leader in liquid biopsy technology, has reported encouraging results from a study using its Parsortix system to predict progression-free survival among ovarian cancer
N4 Pharma PLC (AIM: N4P) Collaboration Agreement with SRI International Inc
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system designed to carry nucleotides to be developed as cancer treatments and vaccines, is delighted to
N4 Pharma PLC (AIM:N4P) Oral Delivery Update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to provide a further positive update on its
N4 Pharma PLC (AIM:N4P) in-vitro siRNA update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments, gene therapy and vaccines, is pleased to provide a further encouraging update
N4 Pharma PLC (AIM:N4P) Patent Grant
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments, gene therapy and vaccines, is pleased to announce that the University of Queensland has informed